Top

Published in:

01-07-2010 | Letter to the Editor

PALB2 mutations in male breast cancer: a population-based study in Central Italy

Authors: Valentina Silvestri, Piera Rizzolo, Ines Zanna, Mario Falchetti, Giovanna Masala, Simonetta Bianchi, Laura Papi, Giuseppe Giannini, Domenico Palli, Laura Ottini

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Excerpt

To the Editor, …

Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A (2010) Male breast cancer. Crit Rev Oncol Hematol 73(2):141–155CrossRefPubMed

Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Gulino A, Giannini G, Bianchi S, Sera F, Palli D (2009) BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat 116(3):577–586CrossRefPubMed

Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165–167CrossRefPubMed

Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM (2009) The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114(3):457–462CrossRefPubMed

Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446(7133):316–319CrossRefPubMed

Thellenberg C, Malmer B, Tavelin B, Grönberg H (2003) Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol 169(4):1345–1348CrossRefPubMed

Hemminki K, Scélo G, Boffetta P, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride M, Kliewer EV, Chia K-S, Pompe-Kirn V, Martos C, Jonasson JG, Li X, Brennan P (2005) Second primary malignancies in patients with male breast cancer. Br J Cancer 92(7):1288–1292

Sauty de Chalon A, Teo Z, Park DJ, Odefrey FA, kConFab, Hopper JL, Southey MC (2009) Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res Treat. doi:10.1007/s10549-009-0673-x

Chen P, Liang J, Wang Z, Zhou X, Chen L, Li M, Xie D, Hu Z, Shen H, Wang H (2008) Association of common PALB2 polymorphisms with breast cancer risk: a case-control study. Clin Cancer Res 14(18):5931–5937

10.

Cao AY, Yu KD, Yin WJ, Jin W, Di GH, Shen ZZ, Shao ZM (2009) Five common single nucleotide polymorphisms in the PALB2 gene and susceptibility to breast cancer in eastern Chinese population. Breast Cancer Res Treat. doi:10.1007/s10549-009-0637-1

Title: PALB2 mutations in male breast cancer: a population-based study in Central Italy
Authors: Valentina Silvestri
Piera Rizzolo
Ines Zanna
Mario Falchetti
Giovanna Masala
Simonetta Bianchi
Laura Papi
Giuseppe Giannini
Domenico Palli
Laura Ottini
Publication date: 01-07-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0797-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2010

Information from CTC measurements for metastatic breast cancer prognosis—we should do more than selecting an “optimal cut point”

No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects

Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study

High-throughput resequencing in the diagnosis of BRCA1/2 mutations using oligonucleotide resequencing microarrays

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

Induction of the small heat shock protein αB-crystallin by genotoxic stress is mediated by p53 and p73

Keynote webinar | Spotlight on antibody–drug conjugates in cancer